|
|
T-20 (Enfuvirtide, Fuzeon) Research
- Needle-Free Mode of T-20 Dosing Looks Highly Satisfactory for Patients (August 28, 2006)
From aidsmap.com
- HIV JournalView: Disappointing Results With Once-Daily Enfuvirtide (February/March 2006)
- HIV JournalView: Enfuvirtide: Is Needleless Dosing Possible? (February/March 2006)
- Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006 (July 22, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Warns Roche About Misleading Comments Made by Salesperson Regarding Fuzeon (July 20, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Roche, Trimeris Seek FDA Approval to Use Needle-Free Injection Device to Administer Antiretroviral Fuzeon (July 19, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Severe Enfuvirtide Injection Site Reactions Tied to Lack of Subcutaneous Fat (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions (October 22, 2004)
[Archived Article]
From U.S. Food and Drug Administration
- Fuzeon Recommended for CD4 Counts Over 100, Viral Loads Below 100,000 (October 2004)
[Archived Article]
Quick recap of recommendations published in the journal AIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
- HIV JournalView: Long-Term Resistance Patterns on Enfuvirtide (September 2004)
[Archived Article]
From The Body PRO
- Enfuvirtide Benefits Persist for at Least 2 Years (July 12, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Global Guidelines Published on Enfuvirtide Use (May 18, 2004)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Drug Development News: Trimeris (May/June 2004)
[Archived Article]
Efforts are under way to improve the delivery method of T-20.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Enfuvirtide Safe and Effective for Adolescents (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
[Archived Article]
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Food and Drug Administration Approves First in Class of AIDS Drugs (March 14, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (March 13, 2003)
[Archived Article]
Results published early from the TORO-1 study investigating T-20 in treatment-experienced patients.
To read PDF, click here
In New England Journal of Medicine
- Fuzeon (T-20), the First HIV Entry Inhibitor, Is Now FDA-Approved (Spring 2003)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
- Fuzeon Data Review (March 2003)
[Archived Article]
A capsule review of T-20 efficacy data from TORO 1 and TORO 2.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Anti-HIV Drug Updates -- Three Drugs on the Near Horizon (January 2003)
[Archived Article]
Research from Barcelona on T-20, atazanavir and emtricitabine.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Anti-HIV Drug Updates: T-20 (Enfuvirtide/Fuzeon) (January 2003)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Boulder Blues (January/February 2003)
[Archived Article]
Roche meets with ADAPs and activists to discuss T-20 (Fuzeon) pricing.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Informed Access to T-20 Planned (January/February 2003)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- New Anti-HIV Therapies: Pentafuside (T-20) (January 2003)
[Archived Article]
From Project Inform
- Research From the 42nd ICAAC: T-20 License -- and Ultimate Trial -- Loom (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Study Shows T-20 Highly Effective as Regimen Booster (November 19, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- T-20 May Help Expand Number of Treatable Groups (September 30, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Digging Deeper at the Resistance Workshop (August 14, 2002)
[Archived Article]
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Long-Term Treatment With Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily Living (August 6, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- T-20 Study Data Promising (June/July 2002)
[Archived Article]
In Positive Living, from AIDS Project Los Angeles
- AIDS Drug Fares Well in Big Trial (April 19, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- T-20: Will Long-Term Use Weaken the Immune System's Ability to Fight HIV? (June 11, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Experimental Entry Inhibitor Drugs (Spring 2001)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Low-Dose Ritonavir and Efavirenz in Non-Nucleoside-Naive Protease-Inhibitor-Experienced HIV-1 Infected Adults (February 8, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- AIDS Researchers Explore New Drug Options (March 1, 2000)
[Archived Article]
In Journal of the American Medical Association
- Fusion Inhibitors (September/October 1999)
[Archived Article]
T-20 (Pentafuside) and T-1249.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- T-20: 5-Drug Combination Trial for Heavily Treated NNRTI-Naive Patients (July 16, 1999)
[Archived Article]
From AIDS Treatment News
- Safety, Pharmacokinetics, and Antiviral Activity of T-20 as a Single Agent in Heavily Pre-Treated Patients (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- T-20 Results Published (November 6, 1998)
[Archived Article]
From AIDS Treatment News
- Fusion Inhibitors, T-20; Chemokine Variants; Tat and Interferon Antibodies: Gallo Describes Three New Treatment Approaches (July 17, 1998)
[Archived Article]
From AIDS Treatment News
- T-20 and Trimeris (April 17, 1998)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- T-20: Entirely New Antiretroviral (September 19, 1997)
[Archived Article]
From AIDS Treatment News
|
Advertisement
|
E-Mail
Glossary
Share